PulmOne Advanced Medical Devices

Prof. Jeffrey J. Fredberg

Prof. Jeffrey J. Fredberg is a professor of BioEngineering and Physiology at the Harvard School of Public Health. He joined PulmOne’s Scientific Advisory Board in 2010.

Prof. Fredberg served on the editorial boards of the Journal of Applied Physiology, Respiratory Research, American Journal of Physiology and Mechanics & Chemistry of Biosystems.

Prof. Fredberg’s many past and present roles include serving on the ATS board of directors, NIH Respiratory Sciences Study Section Boundary Team, the NSF/NIH Interagency Panel on Bridging the Life and Physical Sciences, the NHLBI Working Group on Nanotechnology in Heart, Lung, Blood, and Sleep Medicine, and the Heart, Lung, and Blood Program Project Review Committee (study section HLBP) of the NHLBI.

Prof. Robert Brown

Prof. Robert Brown is Director of Pulmonary Function Laboratory and the Medical Director of the Respiratory Acute Care Unit at the Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. He joined PulmOne’s Scientific Advisory Board in 2010.

Prof. Brown served on the editorial boards of Medicine International, the Journal of the American Paraplegia Society (section editor), the Journal of Spinal Cord Injury Medicine (section editor), the Journal of Spinal Cord Injury Medicine (associate editor) and the Archives of Physical Medicine and Rehabilitation.

Avi Lazar

Avi Lazar founded PulmOne Advanced Medical Devices Ltd. in March 2006, and has been serving as CEO since its inception. Prior to PulmOne, Avi served as Chief Executive Officer and Chief Financial Officer in several Israeli technology companies, where he was instrumental in raising over $50 million from prominent financial and strategic investors, such as Cisco Systems, Lehman Brothers, Philips, JP Morgan Partners, Texas Instruments, ABN Amro and others. Avi has also served on a number of Boards. Before these corporate activities, Avi held senior positions with international accounting firm Ernst & Young, where he was responsible for several successful initial public offerings in NASDAQ and TASE.

Dr. Marc Rothenberg

Dr. Rothenberg is the Director of the Division of Allergy and Immunology at Cincinnati Children’s Hospital Medical Center (Cincinnati Children’s), a tenured Professor of Pediatrics at Cincinnati Children’s and the University of Cincinnati College of Medicine (UCCOM), the Founder and Director of the Cincinnati Center for Eosinophilic Disorders (CCED), and the Founder and Director of the NIH-sponsored, national Consortium of Eosinophilic Disease Researchers (CEGIR).

He graduated summa cum laude with Highest Honors in Chemistry and Biochemistry from Brandeis University. At Harvard Medical School (HMS), he completed the combined MD/PhD program. After completing a residency in pediatrics at Children’s Hospital in Boston, Dr. Rothenberg did a combined fellowship in Allergy/Immunology and Hematology at Children’s Hospital and a post-doctorate training in Boston. He came to the UCCOM and Cincinnati Children’s in 1996 and has helped build a top program in pediatric research; his division is a leader in pediatric allergy and immunology.

His research is focused on molecular analysis of allergic inflammation. Dr. Rothenberg’s awards include the 2007 E. Mead Johnson Award from the Society of Pediatric Research, an NIH MERIT Award in 2010 and he is a member of the Hewlett-Woodmere Alumni Hall of Fame. He is an elected member of the ASCI, AAP, AAAS and SPR. His publications number over 325. He has served on various review panels for journals and grant agencies including the NIH, Burroughs Trust, the MRC of the UK and the ISF of Israel. He is an Associate Editor of the Journal of Allergy and Clinical Immunology, and Mucosal Immunology, and co-Section Head of the Allergy and Hypersensitivity Section of Faculty 1000. He is the Inventor of over 20 patents, issued or pending. He has served as a key Consultant to a number of Start-Up Companies that have subsequently become public entities. He has served a four-year term on the Advisory Council of the NIAID. His research has been supported by numerous sources including the NIH, Human Frontier Science Program Organization, the Burroughs Wellcome Fund, the Dana Foundation, the US Department of Defense, US-Israel Binational Fund, and PCORI. He has trained a myriad of clinical and research investigators in his own laboratory and also as Program Director and/or Co-Principal Investigator of several NIH training grants including the NIH CTSA KL2, NICHD CHRCDA K12, and NIAID T32.

Amit Morag

Amit Morag has 15 years of experience in the high technology industry. Prior to joining PulmOne, Amit served in various Operations, Engineering, Service and Product leadership roles, mainly in the medical devices and telecommunications industries, including General Electric Healthcare. Amit holds a B.Sc in Engineering and MBA, both from Tel-Aviv University.

Scott Yokobosky

Prior to joining PulmOne, Scott was a Regional Manager in rare and orphan diseases at Mallinckrodt Neurology, and Director of Managed Care covering United Health Care at Schering Oncology. Previously, he was the National Sales Director of Rheumatology at Horizon Pharma. Scott has held several sales leadership roles in Oncology, Rheumatology, Orthopedic Medical Devices and Pulmonology at companies including Sanofi Oncology and Praecis Biotech.

Harold Smeets

Harold brings to PulmOne over 30 years’ experience in the field of cardiorespiratory diagnostics, specializing in lung function physics and physiology. He has held several senior leadership roles in international sales, upstream and downstream marketing, and technical product management at a number of respiratory diagnostics companies including Carefusion and Ganshorn.

About

Company

Team